SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending due to escalating geopolitical tensions in the Middle East involving the US and Iran, sparking a highly divided community debate between those anticipating a significant market downturn and others who view it as a "buy the dip" opportunity, arguing the events are already priced in.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as escalating geopolitical tensions in the Middle East, including military actions and potential disruptions to the Strait of Hormuz, are driving strong community anticipation for rapidly surging oil prices. Traders view XOM as a prime beneficiary and a key hedge against the broader market volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amidst escalating Middle East tensions, with market participants sharply divided between expectations of a significant tech sell-off due to rising oil prices and concerns over global stability, versus a 'buy the dip' mentality fueled by beliefs of market resilience and potential liquidity injections.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amidst escalating geopolitical tensions in the Middle East, with oil prices surging due to fears of supply disruptions and the potential closure of the critical Strait of Hormuz. The community anticipates a significant upward move for low-float oil stocks like INDO, with many discussing a potential short squeeze and drawing comparisons to previous parabolic runs driven by global conflicts.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending amidst escalating geopolitical tensions in the Middle East and increased U.S. military deployments, leading the community to anticipate sustained demand for its defense systems, including F-35 jets and missile production.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is heavily trending amid escalating geopolitical tensions in the Middle East, with community discussion centered on the potential for massive defense orders and a significant short squeeze for drone stocks. Investors are highlighting Ondas's strategic position in defense initiatives, including its Israeli partnerships and participation in the U.S. Drone Dominance Program, driving expectations for a substantial upside.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

Escalating U.S.-Israeli strikes on Iran, followed by Iranian retaliation and a halt in tanker traffic through the critical Strait of Hormuz, are intensely fueling discussion around USO as the community debates a potential "war premium" spike versus a temporary "sell the news" event amid broader inflation concerns.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as escalating geopolitical tensions fuel investor speculation about increased demand for its FPV 'kamikaze' drones and uncrewed surface vessels (USVs) for defense. The community is actively discussing the immediate relevance of its Black Widow and FANG drones to current conflicts and the potential for significant contract awards from the US Army's 'Drone Dominance' program.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as community debate intensifies over recent geopolitical events driving market volatility and creating a "buy the dip" opportunity. This comes amidst news of a powerful new AI inference chip and strategic 6G partnerships anticipated ahead of its developer conference.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

The Pentagon's deal with OpenAI is driving conversation around Microsoft as a key beneficiary in government AI, especially after a rival's blacklisting, though community sentiment remains polarized following recent share price declines and ongoing concerns about AI infrastructure spending and broader market shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold

Wall Street Zen cut shares of Akebia Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS).</li><li>In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.</li><li>The company ended Q4 with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.</li></ul>&nbsp;Shares of Akebia Therapeutics Inc (AKBA) rose 7% on Thursday after the company announced that it expects significant revenue growth for its approved anemia medicine Vafseo in 2026 while it also advances its clinical pipeline.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025">said</a> on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. Akebia acquired the experimental drug from Q32 Bio in November. The company will explore the drug in IgA nephropathy, lupus nephritis and C3 glomerulopathy, it said.Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS). Target enrollment for the trial is approximately 60 patients.<h2 class="st-heading-2">Future Of FDA-Approved Medicines</h2>Akebia has two medicines approved by the U.S. Food and Drug Administration including <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Vafseo </a>for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients. In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.“Vafseo commercial trends are showing marked improvement in early 2026... Patient access to Vafseo therapy now stands at 290,000 patients, and early data points to improved patient adherence rates, which we believe are enhanced as a result of dialysis organizations deciding to implement observed dosing protocols. These dynamics, along with the building evidence of clinical differentiation, are expected to drive significant Vafseo revenue growth in 2026 and beyond…, ” said CEO John P. Butler.<h2 class="st-heading-2">Q4 Numbers</h2>For the fourth quarter, the company reported net product revenues of $54.3 million, owing to a quarter-on-quarter increase in prescribers for Vafseo which was launched in the U.S. in Jan. 2025 and an increase in sales volume for Auryxia. Analysts on average were expecting the company to report revenue of $46.09 million.Net loss per share for the period came in at $0.05, compared to a loss of $0.10 in the corresponding quarter of 2024, but above an analyst estimate of a loss of $0.04.The company ended the quarter with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AKBA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user highlighted the several potential catalysts for the stock including accelerating adoption for Vafseo and cash hoard.<stembedurl>https://www.stocktwits.com/ROCKET123/message/645988666</stembedurl>Another voiced hopes for stock as much as doubling “sooner or later.”<stembedurl>https://www.stocktwits.com/Andi77/message/645980832</stembedurl><a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-falls-michael-burry-says-nvidia-purchase-commitments-akin-to-cisco-dot-com-bubble/cZTGi6FRIRb">Michael Burry Warns Nvidia’s ‘Purchase Commitments’ Akin To Cisco At The Top Of Dot-Com Bubble — NVDA Stock Falls 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Equity

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.


Akebia Therapeutics Q4 Earnings Call Highlights

Akebia Therapeutics (NASDAQ:AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic...

Akebia Therapeutics, Inc. Q4 Loss Decreases

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) revealed Loss for fourth quarter of -$12.24 million...

Akebia Therapeutics Q4 Earnings Report: What Investors Need to Know

Uncovering Potential: Akebia Therapeutics's Earnings Preview

BTIG Research Has Lowered Expectations for Akebia Therapeutics (NASDAQ:AKBA) Stock Price

BTIG Research lowered their target price on Akebia Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat...

Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Akebia Therapeutics Inc.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$1.31
Prev Close	$1.32
Open	$1.30
Dividend Yield	0.00%
50-Day Moving Average	$1.44
Beta	1.35
Avg. Volume	2.99M
PE Ratio	-17.21

52-Week High	$4.08
52-Week Low	$1.14
Market Capitalization	$350.92M
EPS (Annual)	-$0.0208
Price to Book	8.35
Revenue Per Employee	$1.22M

AKBA
Akebia Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKBA News

AKBAAkebia Therapeutics Inc.